Design Therapeutics vs Entrada Therapeutics
DSGN and TRDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DSGN and TRDA compare
Design Therapeutics is the larger company, worth 3.2 times as much as Entrada Therapeutics ($674M against $212M).
Design Therapeutics scores higher on the StockData Score (7 against 6 for Entrada Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DSGN | TRDA |
|---|---|---|
| Size and price | ||
| Market cap | $674M | $212M |
| Share price | $10.77 | $5.44 |
| Change, 1 year | 45.0% | −25.1% |
| Change, 5 years | −47.5% | −83.4% |
| Beta (5Y) | 1.69 | 0.97 |
| Employees | 54 | 152 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 53.3× |
| P/B | 3.3× | 1.1× (better) |
| FCF yield | −8.8% (better) | −64.4% |
| Growth | ||
| Revenue growth (TTM) | – | −93.5% |
| Profitability | ||
| Operating margin | – | −4304% |
| Net margin | – | −4058% |
| FCF margin | – | −3428% |
| Return on equity | −36.9% (better) | −59.9% |
| Return on invested capital | – | −1406% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 16.78 (better) | 7.85 |
| Altman Z-score | 25.24 (better) | −1.53 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Buyback yield | −9.2% | – |
| Shareholder yield | −9.2% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 69.2% | 75.6% |
| Held by insiders | 21.2% | 14.8% |
| Insider net buying, 12 months | – | −$11.5M |
| Short interest, % of float | 12.8% | 8.5% |
Go deeper
- DSGN stock overview
- DSGN income statement
- DSGN valuation and score
- TRDA stock overview
- TRDA income statement
- TRDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.